Soleno Therapeutics Inc (SLNO) — Cash Flow Quality Index

Latest as of March 2026: 0.83x

Soleno Therapeutics Inc (SLNO) has a Cash Flow Quality Index of 0.83x as of March 2026. Operating cash flow of $25.98 Million is below net income of $31.38 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore Soleno Therapeutics Inc (SLNO) cash flow conversion to assess how effectively this company generates cash.

Cash Flow Quality Index

0.83x
Operating CF / Net Income

Operating Cash Flow

$25.98 Million
USD

Net Income

$31.38 Million
USD

Data as of

Mar 2026
Most recent filing

Soleno Therapeutics Inc Cash Flow Quality Index (2025–2025)

Historical Cash Flow Quality Index for Soleno Therapeutics Inc across 1 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check total reinvestment intensity of Soleno Therapeutics Inc to assess the company's total reinvestment commitment from operating cash flow.

Annual Cash Flow Quality Index for Soleno Therapeutics Inc (2025–2025)

Year-by-year earnings quality comparison for Soleno Therapeutics Inc. For live market cap and the full company financial profile, see Soleno Therapeutics Inc market cap and net worth.

Year Quality Index Operating CF (USD) Net Income YoY Change
2025 2.24x $46.80 Million $20.89 Million
Cash Flow Quality Index = Operating Cash Flow / Net Income. Ratios above 1.0x indicate cash-backed earnings.